Jill M. Broadfoot
2023 - aTYR PHARMA
In 2023, Jill M. Broadfoot earned a total compensation of $677.8K as Chief Financial Officer at aTYR PHARMA, a 26% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $116,031 |
|---|---|
| Option Awards | $133,084 |
| Salary | $414,395 |
| Other | $14,327 |
| Total | $677,837 |
Broadfoot received $414.4K in salary, accounting for 61% of the total pay in 2023.
Broadfoot also received $116K in non-equity incentive plan, $133.1K in option awards and $14.3K in other compensation.
Rankings
In 2023, Jill M. Broadfoot's compensation ranked 1,669th out of 3,006 executives tracked by ExecPay. In other words, Broadfoot earned more than 44.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,669 out of 3,006 | 45th |
Division Manufacturing | 974 out of 1,650 | 41st |
Major group Chemicals And Allied Products | 624 out of 918 | 32nd |
Industry group Drugs | 608 out of 881 | 31st |
Industry Biological Products, Except Diagnostic Substances | 163 out of 213 | 24th |
Source: SEC filing on April 5, 2024.
Broadfoot's colleagues
We found two more compensation records of executives who worked with Jill M. Broadfoot at aTYR PHARMA in 2023.
News
aTYR PHARMA CEO Sanjay Shukla's 2023 pay falls 46% to $1.3M
April 5, 2024
aTYR PHARMA CEO Sanjay Shukla's 2021 pay jumps 75% to $1.9M
March 22, 2022
aTYR PHARMA CEO Sanjay Shukla's 2020 pay jumps 63% to $1.1M
March 23, 2021
aTYR PHARMA CEO Sanjay Shukla's 2019 pay falls 52% to $664K
April 2, 2020
aTYR PHARMA CEO Sanjay Shukla's 2018 pay falls 36% to $1.4M
March 28, 2019